Skip to main content

AzaSite FDA Approval History

FDA Approved: Yes (First approved April 27, 2007)
Brand name: AzaSite
Generic name: azithromycin
Dosage form: Ophthalmic Solution
Company: InSite Vision Incorporated
Treatment for: Conjunctivitis, Bacterial

AzaSite is an ophthalmic formulation of the well-known, broad-spectrum antibiotic azithromycin indicated for the treatment of bacterial conjunctivitis.

Development timeline for AzaSite

Apr 29, 2007Approval Inspire Announces FDA Approval Of AzaSite
Aug 28, 2006InSite Vision Announces FDA Acceptance of New Drug Application for Review
Jun 29, 2006InSite Vision Announces Submission of AzaSite NDA
Apr 27, 2006InSite Vision Meets With the FDA on Pre-NDA Discussions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.